Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

139.79 -2.95 (-2.07%)
Official Closing Price Updated: 7:00 PM EDT, Jul 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,837,831
Open 142.27
Bid (Size) 139.07 (1)
Ask (Size) 140.00 (1)
Prev. Close 142.74
Today's Range 138.80 - 142.53
52wk Range 75.96 - 148.15
Shares Outstanding N/A
Dividend Yield 1.26%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Eli Lilly, Novo Nordisk Shares Dip As Pfizer Ramps Up Diabetes Drug Competition
Shares of Eli Lilly and Co (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) are facing declines Thursday, maybe influenced by competitive developments and regulatory updates in the pharmaceutical sector. 
Via Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations. 
Via Benzinga

Performance

YTD
+36.90%
+36.90%
1 Month
-1.41%
-1.41%
3 Month
+11.48%
+11.48%
6 Month
+31.02%
+31.02%
1 Year
+80.67%
+80.67%

More News

Read More
FDA Rejects Novo Nordisk's Weekly Insulin, Requests Information Related To Manufacturing Process, Type 1 Diabetes
Via Benzinga
Exposures Product Safety
EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year
Via Benzinga
Chipotle Just Did a Stock Split. History Says This Is What Might Happen Next.
Via The Motley Fool
Will NVO Provide Any Buying Opportunity?
Via Talk Markets
Jim Cramer Identifies Eight Companies Eyeing Trillion-Dollar Club — Elon Musk's Tesla, Eli Lilly Top Contenders
Via Benzinga
3 Pharma Stocks That Could Make Your Grandchildren Rich
Via InvestorPlace
Only 25% Patients Stick With Novo Nordisk's Wegovy Or Ozempic After 2 Years, A Study Shows; Company Calls Data Insufficient
Via Benzinga
Stay Away: Why Ginkgo Bioworks Stock Is Not for the Faint-Hearted
Via InvestorPlace
Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
Via MarketBeat
7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
Via InvestorPlace
3 Stocks With the Potential to 10X Your Money
Via InvestorPlace
Eli Lilly Rose More Than 50% So Far This Year. Can It Soar Past $1,000 in the 2nd Half?
Via The Motley Fool
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Via Benzinga
Patients Lost More Weight On Eli Lilly's Mounjaro Than Novo Nordisk's Ozempic
Via Investor's Business Daily
3 Overlooked Giants-in-the-Making for Patient Investors
Via InvestorPlace
Novartis Stock Generating Improved Relative Strength
Via Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
The 7 Best Under $10 Stocks to Buy in July 2024
Via InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Via Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
Via MarketBeat
Topics Economy
Exposures Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
Via Benzinga
Ozempic Maker Novo Nordisk Reprimanded by UK Regulators for Payment Disclosure Failures
Via Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.